- $808.80m
- $583.05m
- $76.30m
- 50
- 15
- 36
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.39 | ||
| Price to Tang. Book | 2.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.58% | ||
| Return on Equity | -30.54% | ||
| Operating Margin | -179.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 38.95 | 26.68 | 412.48 | 76.01 | 76.3 | 94.48 | 166.07 | 20.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 30th, 2022
- Public Since
- June 24th, 2019
- No. of Shareholders
- 80
- No. of Employees
- 280
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 70,147,520
- Address
- 108 Patriot Drive, Suite A, MIDDLETOWN, 19709
- Web
- https://www.zymeworks.com/
- Phone
- +1 3022748744
- Auditors
- KPMG LLP
Upcoming Events for ZYME
Q1 2025 Zymeworks Inc Earnings Call
Q2 2025 Zymeworks Inc Earnings Release
Similar to ZYME
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Zymeworks share price?
As of Today at 24:17 UTC, shares in Zymeworks are trading at $11.53. This share price information is delayed by 15 minutes.
How has the Zymeworks share price performed this year?
Shares in Zymeworks last closed at $11.53 and the price had moved by +30.28% over the past 365 days. In terms of relative price strength the Zymeworks share price has outperformed the S&P500 Index by +22.5% over the past year.
What are the analyst and broker recommendations for Zymeworks?
The overall consensus recommendation for Zymeworks is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Zymeworks dividend yield?
Zymeworks does not currently pay a dividend.
Does Zymeworks pay a dividend?
Zymeworks does not currently pay a dividend.
When does Zymeworks next pay dividends?
Zymeworks does not currently pay a dividend.
How do I buy Zymeworks shares?
To buy shares in Zymeworks you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zymeworks?
As of the previous close price of $11.53, shares in Zymeworks had a market capitalisation of $808.80m.
Where are Zymeworks shares listed?
Here are the trading details for Zymeworks:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ZYME
What kind of share is Zymeworks?
Based on an overall assessment of its quality, value and momentum Zymeworks is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zymeworks share price forecast for 2025?
The analyst consensus target price for shares in Zymeworks is $22.39. That is 94.19% above the last closing price of $11.53.
Analysts covering Zymeworks currently have a consensus Earnings Per Share (EPS) forecast of -$1.67 for the next financial year.
Find out moreWhat is the trend in the Zymeworks share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zymeworks. Over the past six months, its share price has underperformed the S&P500 Index by -5.22%.
As of the last closing price of $11.53, shares in Zymeworks were trading -9.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zymeworks PE Ratio?
The Zymeworks PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zymeworks?
Zymeworks' management team is headed by:
- Kenneth Galbraith - CHM
- Neil Klompas - CFO
- Neil Josephson - OTH
- Lota Zoth - LED